321 related articles for article (PubMed ID: 23777956)
1. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.
Wigle J; Coast E; Watson-Jones D
Vaccine; 2013 Aug; 31(37):3811-7. PubMed ID: 23777956
[TBL] [Abstract][Full Text] [Related]
2. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
3. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
5. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
7. Progress in HPV vaccination in low- and lower-middle-income countries.
LaMontagne DS; Bloem PJN; Brotherton JML; Gallagher KE; Badiane O; Ndiaye C
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():7-14. PubMed ID: 28691329
[TBL] [Abstract][Full Text] [Related]
8. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR).
Soi C; Gimbel S; Chilundo B; Muchanga V; Matsinhe L; Sherr K
Implement Sci; 2018 Dec; 13(1):151. PubMed ID: 30545391
[TBL] [Abstract][Full Text] [Related]
10. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
[TBL] [Abstract][Full Text] [Related]
11. Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low- and middle-income countries.
Guillaume D; Waheed DE; Schleiff M; Muralidharan KK; Vorsters A; Limaye RJ
PLoS One; 2024; 19(1):e0291990. PubMed ID: 38227567
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
14. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
Slavkovsky R; Callen E; Pecenka C; Mvundura M
Vaccine; 2024 Feb; 42(6):1200-1210. PubMed ID: 38302338
[TBL] [Abstract][Full Text] [Related]
15. Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government-implemented demonstration program.
LaMontagne DS; Nghi NQ; Nga le T; Janmohamed A; Huyen DT; Hien NT; Tsu VD
BMC Public Health; 2014 Jun; 14():556. PubMed ID: 24898950
[TBL] [Abstract][Full Text] [Related]
16. Lessons learned from HPV vaccine delivery in low-resource settings and opportunities for HIV prevention, treatment, and care among adolescents.
Tsu VD; Cernuschi T; LaMontagne DS
J Acquir Immune Defic Syndr; 2014 Jul; 66 Suppl 2():S209-16. PubMed ID: 24918597
[TBL] [Abstract][Full Text] [Related]
17. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
18. Overcoming barriers and ensuring access to HPV vaccines in low-income countries.
Tsu VD
Am J Law Med; 2009; 35(2-3):401-13. PubMed ID: 19697756
[TBL] [Abstract][Full Text] [Related]
19. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.
Wong LP; Han L; Li H; Zhao J; Zhao Q; Zimet GD
Hum Vaccin Immunother; 2019; 15(7-8):1533-1540. PubMed ID: 31017500
[TBL] [Abstract][Full Text] [Related]
20. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
